Breast Cancer, Colo-rectal Cancer
Conditions
Keywords
ctDNA, Molecular karyotype
Brief summary
There are several types of circulating DNA: DNA from patient's existing cells, foetal DNA in the case of pregnant woman, and tumoral DNA in the case of patients with cancer. These circulating tumoral DNA (ctDNA) can be obtained from a blood test called liquid biopsy and be detected by the latest generation of very high throughput sequencers with the Massive Parallel Sequencing technique (MPS). This study focus on using this technique on breast and colorectal cancers in which no analysis of CNV (tumor origin marker) with this technique has been performed yet. It is a prospective, pilot, monocentric, feasibility study on genomic profile. The study aim is to show the possibility to realize in a reproductive way a molecular karyotype on ctDNA with the MPS approach from a liquid biopsy taken from patients with cancer and to compare this profile with the one obtained by CGH array (Comparative Genomic Hybridization) from primitive tumor.
Interventions
PROCEDUREBlood samples
30 ml of blood collection
Sponsors
Centre Hospitalier Henri Duffaut - Avignon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Signed consent * Women with invasive breast carcinoma, NOS, with a radiologically measurable tumor of more than 10 mm (stade I to III) * Patients with invasive colorectal adenocarcinoma with a radiologically measurable tumor of more than 10 mm (stade I to III) * Patients who primary surgery is planned
Exclusion criteria
* Neoadjuvant chemotherapy or neoadjuvant radiotherapy * Other cancer * BMI \> 30 * Pregnant woman * Patients under protective administration or deprived of liberty
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV) | Up to surgery | Feasibility of molecular karyotype showing acquired copies number variations (CNV) on whole genome performed from ctDNA isolated from blood sample in patients with breast or colorectal cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of patient's tumor genomic profile with blood sample | Up to surgery | Identification of patient's tumor genomic profile by comparison between genomic profile of primitive tumor obtained by CGH array and genomic profile of ctDNA obtained by Massive Parallel Sequencing |
Countries
France
Outcome results
None listed